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Purpose
The effectiveness of cancer immunotherapy can be com-
promised when immune cells cannot penetrate the tumor.
We hypothesize that combining an antiangiogenic tyrosine
kinase inhibitor (TKI) with a cancer vaccine can increase
antitumor response by targeting 3 elements of the tumor
microenvironment (TME): (a) tumor endothelial cells,
which can lead to vascular normalization; (b) tumor cells,
which can reduce tumor compactness and allow collapsed
vessels to reopen; (c) tumor infiltrating immune cells,
which can increase the frequency and function of effector
immune elements, i.e. tumor-infiltrating lymphocytes
(TILs) and anti-tumor myeloid cells, and decrease number
and function of immune suppressor cells, i.e. T-regulatory
lymphocytes (Tregs), myeloid-derived suppressor cells
(MDSCs), and immune suppressive tumor-associated
macrophages (TAMs).
Methods
Animal studies were conducted using antiangiogenic
TKIs (sunitinib or sorafenib) in combination with
recombinant vaccines in 2 murine tumor models: colon
carcinoma (MC38-CEA) and breast cancer (4T1). Tumor
vasculature was measured by immunohistochemistry
for the identification of mature (CD31+), immature/
proliferating (CD105+), and monocytic (CD11b+)
endothelial cells. Tumor oxygenation, tight junctions,
compactness, and tissue pressure were assessed after
treatment with either TKI alone, vaccine alone, or combi-
nation. In addition, the frequency and phenotype of TILs,
MDSCs, and TAMs were evaluated.
Results
The combination of either TKI with vaccine decreased
tumor vasculature, compactness, tight junctions, and
pressure, leading to vascular normalization and
increased tumor oxygenation. Combination therapy
increased TILs, including tumor antigen-specific CD8
T-cells, and elevated expression of the activation mar-
kers FAS-L, CXCL-9, CD31, and CD105 in MDSCs and
TAMs, leading to reduced tumor volumes and an
increased number of tumor-free animals.
Conclusions
The improved antitumor activity induced by combining
antiangiogenic TKIs with vaccine may be due to the
immunologic effects of vascular normalization within
tumors. The improved vascular perfusion facilitated the
penetration, while the increased tumor oxygenation
increased the activation of lymphoid and myeloid cells
in the TME. These microarchitectural and immunologic
changes in the TME acted in synergy with the tumor-
associated antigen-specific immune activation elicited by
therapeutic vaccination. Therapies that alter tumor
architecture can thus have a dramatic impact on the
effectiveness of cancer immunotherapy.
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